Content area
Full text
Zogenix Inc., a San Diego-based pharmaceutical company making products for the treatment of pain-related and central nervous system disorders, announced that it has acquired Brabant Pharma, a privately-held U.K.-based pharmaceutical company for $20 million in cash and $15 million in stock, plus potential future milestone and royalty payments.
The acquisition includes worldwide development and commercialization rights to Brabafen, a treatment for Dravet syndrome, a rare form of epilepsy that begins in infancy. Brabafen has recently received orphan drug designation in Europe and the U.S. for the treatment of Dravet syndrome.
...